Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Vogt Koyanagi Harada Disease Clinical Trial

Official title:
Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Status Withdrawn

Clinical Trial Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00407121
Study type	Interventional
Source	Asociación para Evitar la Ceguera en México
Contact
Status	Withdrawn
Phase	Phase 3
Start date	December 2006
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03399175` - Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease	N/A
Recruiting	`NCT05496530` - Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results)	N/A
Completed	`NCT05031143` - Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment	Phase 2/Phase 3